Long-term Fertility After Lymphoma Treatment in Young Women
Official title: Long-term Follow-up of Ovarian Function and Fertility in Young Lymphoma Patients Treated by Chemotherapy
Run by University Hospital, Lille · NCT05616325 · Data updated 2026-11-12
This observational study follows young women who had lymphoma and chemotherapy to see how their ovarian reserve changes years after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | Women only |
| Enrollment | 270 (estimated) |
| Sponsor | University Hospital, Lille Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Lille) |
| Status | Recruiting |
| Started | August 22, 2023 |
| Main results expected | March 2029 |
| Study ends | March 2029 |
| Registry record updated | May 22, 2026 |
| Trial ID | NCT05616325 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women with a history of lymphoma treated with chemotherapy who are at least five years post-treatment and followed at the Lille fertility observatory.
✕Probably not a fit
Patients not meeting the five-year post-treatment window or not followed at the Lille fertility observatory may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, longitudinal cohort study that tracks ovarian reserve in lymphoma patients who received chemotherapy. AMH levels are measured before, during, and after treatment to understand how different chemotherapy regimens affect long-term fertility. The study aims to inform preservation strategies and patient counseling about future pregnancy chances. Participation requires being treated at the Lille fertility observatory, at least five years after chemotherapy, and providing informed consent.
Why it matters
Potential benefit: Findings could help doctors tailor fertility preservation and counseling for lymphoma survivors.
How similar studies have gone: Prior research has shown AMH declines during chemotherapy and partial recovery after completion, supporting the plausibility of long-term ovarian impact assessment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a history of lymphoma treated with chemotherapy * followed in the fertility observatory of the Jeanne de Flandre Hospital at the University Hospital of Lille (project "she will heal and then want a child"), who are at least at 5 years since the end of chemotherapy * Patients having been informed and having given their written consent to participate in the study. * Beneficiary of a social security system. Exclusion Criteria: * Patient not followed in the fertility observatory. * Inability of the patient to undergo the medical follow-up of the trial for geographical, social or psychological reasons. * Patient opposed to her participation in the study. * Patient under guardianship or curatorship.
Where it's running
-
chu de Lille
Lille, France Recruiting
Study contacts
- Principal investigator: Christine DECANTER, MD,PhD — University Hospital, Lille
- Study coordinator: Christine DECANTER, MD,PhD
- Email: christine.decanter@chru-lille.fr
- Phone: 0320445962
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MK-1045 for follicular lymphoma and diffuse large B-cell lymphoma
This trial tests MK-1045 in people with follicular lymphoma or diffuse large B-cell lymphoma to see if the treatment is safe and tolerable and whether the cancer shrinks or disappears.
-
New therapy dose test for people with prior B-cell cancers
This early-phase study tests different doses of LY4152199 to see if it is safe and effective for people who have already been treated for certain B-cell lymphomas.
-
Comparing bone marrow in patients with follicular lymphoma and healthy controls
This study looks at the differences in bone marrow cells between people with follicular lymphoma and healthy individuals to better understand what might cause relapses in the disease.
-
CAR T Cell Therapy for Resistant B-cell Cancers
This study is testing a new CAR T cell therapy to see if it can safely help people with tough-to-treat B-cell cancers like leukemia and lymphoma.
-
Treatment of B-cell malignancies with ALETA-001
This study is testing a new treatment called ALETA-001 to see if it can help people with relapsed non-Hodgkin lymphoma who didn't respond well to previous therapies.
-
Treatment of early relapse follicular lymphoma with mosunetuzumab
This study is testing if a new treatment called mosunetuzumab can help adults with follicular lymphoma who have had a relapse within two years feel better and live longer compared to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.